ID
26761
Beschrijving
A Study of Herceptin (Trastuzumab)and Biomarkers in Patients With HER2-Positive Metastatic Breast Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT00885755
Link
https://clinicaltrials.gov/show/NCT00885755
Trefwoorden
Versies (1)
- 24-10-17 24-10-17 -
Houder van rechten
See clinicaltrials.gov
Geüploaded op
24 oktober 2017
DOI
Voor een aanvraag inloggen.
Licentie
Creative Commons BY 4.0
Model Commentaren :
Hier kunt u commentaar leveren op het model. U kunt de tekstballonnen bij de itemgroepen en items gebruiken om er specifiek commentaar op te geven.
Itemgroep Commentaren voor :
Item Commentaren voor :
U moet ingelogd zijn om formulieren te downloaden. AUB inloggen of schrijf u gratis in.
Eligibility Breast Cancer NCT00885755
Eligibility Breast Cancer NCT00885755
- StudyEvent: Eligibility
Beschrijving
Exclusion Criteria
Alias
- UMLS CUI
- C0680251
Beschrijving
Herceptin Adjuvant | Herceptin Neoadjuvant
Datatype
boolean
Alias
- UMLS CUI [1,1]
- C0338204
- UMLS CUI [1,2]
- C0677850
- UMLS CUI [2,1]
- C0338204
- UMLS CUI [2,2]
- C0600558
Beschrijving
Taxane Adjuvant therapy
Datatype
boolean
Alias
- UMLS CUI [1,1]
- C0215136
- UMLS CUI [1,2]
- C0677850
Beschrijving
Chemotherapy Malignant Neoplasms | Immunotherapy Malignant Neoplasms | Biological treatment Malignant Neoplasms
Datatype
boolean
Alias
- UMLS CUI [1,1]
- C0392920
- UMLS CUI [1,2]
- C0006826
- UMLS CUI [2,1]
- C0021083
- UMLS CUI [2,2]
- C0006826
- UMLS CUI [3,1]
- C1531518
- UMLS CUI [3,2]
- C0006826
Beschrijving
Bleeding tendency
Datatype
boolean
Alias
- UMLS CUI [1]
- C1458140
Similar models
Eligibility Breast Cancer NCT00885755
- StudyEvent: Eligibility
C0001779 (UMLS CUI [2])
C1265611 (UMLS CUI [1,2])
C3900053 (UMLS CUI [1,3])
C1318309 (UMLS CUI [1,4])
C0677850 (UMLS CUI [1,2])
C0338204 (UMLS CUI [2,1])
C0600558 (UMLS CUI [2,2])
C0677850 (UMLS CUI [1,2])
C0006826 (UMLS CUI [1,2])
C0021083 (UMLS CUI [2,1])
C0006826 (UMLS CUI [2,2])
C1531518 (UMLS CUI [3,1])
C0006826 (UMLS CUI [3,2])